
Lilly Oral Orforglipron Beat Placebo on Weight Loss in Japan ATTAIN-J Phase 3, With 12 mg Leading Numerically
Notes de l’épisode
Eli Lilly's once-daily oral GLP-1 drug orforglipron reduced body weight more than placebo at 72 weeks in ATTAIN-J, a Japan-only Phase 3 trial in adults with obesity disease. Mean weight change was −5.9% at 6 mg, −8.7% at 12 mg and −7.9% at 36 mg, versus −0.6% on placebo. At least 5% weight loss was reached by about 46%, 61% and 59% of participants on those doses, versus about 15% on placebo. Side effects were mostly mild-to-moderate gastrointestinal symptoms. The trial compared each dose with placebo and did not prove that one active dose was superior to another.
Sources
- Lancet Diabetes & Endocrinology (ATTAIN-J abstract, published online Oct 30, 2026): thelancet.com
- ClinicalTrials.gov NCT05931380 (ATTAIN-J): clinicaltrials.gov
- Grey Pepper analysis (Nov 5, 2026): greypepper.net
- Diabesity Rounds independent summary (Nov 1, 2026): diabesityrounds.com
- FDA Foundayo (orforglipron) approval announcement (Apr 1, 2026; US labeled doses differ from ATTAIN-J trial strengths): fda.gov
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Tous les épisodes de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News